S. Côté

Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma

R. Fonseca, P. Voorhees, M. Mehra, 2020, BMC Cancer.

The Cost-Effectiveness of Ibrutinib in Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

M. Tambour, S. Sorensen, N. Sengupta, 2016 .

A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.

M. Dimopoulos, N. Munshi, M. Samur, 2020, Blood advances.

Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases

M. Liedtke, A. Dispenzieri, J. Zonder, 2022, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison.

H. Goldschmidt, P. Sonneveld, P. Moreau, 2020, Immunotherapy.

Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison

J. Diels, S. Van Sanden, S. Côté, 2017, Advances in Therapy.

Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching

P. Sonneveld, P. Moreau, C. D. de Boer, 2020, EJHaem.

Matching‐adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible

P. Sonneveld, P. Moreau, T. Facon, 2020, EJHaem.

Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysis.

K. Fahrbach, J. Diels, Yingxin Xu, 2018, Journal of comparative effectiveness research.

Impact of novel agents on patient-relevant outcomes in patients with previously untreated chronic lymphocytic leukemia who are not eligible for fludarabine-based therapy

S. Mealing, S. Côté, S. Baculea, 2017, Journal of medical economics.

Assessing the prognostic utility of hematologic response for overall survival in patients with newly diagnosed AL amyloidosis: results of a meta-analysis

E. Kastritis, J. Vermeulen, A. Wechalekar, 2023, Hematology.

A Matching-Adjusted Indirect Comparison (MAIC) of Daratumumab-Bortezomib-Thalidomide-Dexamethasone (D-VTd) Versus Bortezomib-Lenalidomide-Dexamethasone (VRd) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible

P. Sonneveld, P. Moreau, X. Leleu, 2019, Clinical Lymphoma Myeloma and Leukemia.

A Matching-adjusted Indirect Comparison (MAIC) of Bortezomib-Thalidomide-Dexamethasone (VTd) and Daratumumab Plus VTd (D-VTd) Versus Bortezomib-Dexamethasone (Vd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (TE)

P. Sonneveld, P. Moreau, T. Facon, 2019, Clinical Lymphoma Myeloma and Leukemia.

A Matching-adjusted Indirect Comparison (MAIC) of Bortezomib-Thalidomide-Dexamethasone (VTd) and Daratumumab Plus VTd (D-VTd) Versus Bortezomib-Cyclophosphamide- Dexamethasone (VCd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (TE)

P. Sonneveld, P. Moreau, M. Merz, 2019, Clinical Lymphoma Myeloma and Leukemia.